**CLAIMS**

1. (Canceled)

2. (Currently amended) A compound of formula I



I

wherein

$R_1$ is phenyl or naphthyl, wherein phenyl is substituted by one or two of halogen, $C_{1-6}$-alkyl, $C_{1-6}$-alkoxy or phenyl-$C_{1-6}$-alkyl; and

$R_2$ is hydrogen or $C_{1-6}$-alkyl;

in free, hydrate or salt form.

3. (Currently amended) A compound according to Claim 1 2 which that is selected from 3-(4-(2-ethylphenyl)-2-carboxamido-indole)-alanine, 3-(4-(2-benzyl-phenyl)-2-carboxamido-indole)-alanine, 3-(4-(naphtalen-2-yl)-2-carboxamido-indole)-alanine, 3-(4-(naphtalen-1-yl)-2-carboxamido-indole)-alanine, 3-(4-(2-butoxy-phenyl)-2-carboxamido-indole)-alanine, 3-(4-(2-propyl-phenyl)-2-carboxamido-indole)-alanine, 3-(4-(2-isopropyl-phenyl)-2-carboxamido-indole)-alanine, and 3-(4-(2,4-dichloro-phenyl)-2-carboxamido-indole)-alanine, or a and pharmaceutically-acceptable salts therefor thereof.

4. (Currently amended) A compound according to Claim 3 2 which that is 3-(4-(2-ethylphenyl)-2-carboxamido-indole)-D-alanine, in free form or in a pharmaceutically-acceptable salt form.

5. (Canceled)

6. (Currently amended) A pharmaceutical composition comprising a compound ~~as defined~~ according to Claim ~~1~~ 2, in free form or in pharmaceutically-acceptable salt form, in association with a pharmaceutically-acceptable diluent or carrier ~~therefor~~.

7. (Canceled)

8. (Currently amended) A pharmaceutical combination comprising a compound according to Claim ~~1~~ 2 in free form or in a pharmaceutically-acceptable salt form and a further agent selected from immunosuppressant, immunomodulatory, anti-inflammatory and chemotherapeutic drug agents.

9. (Withdrawn by the Examiner) A process for the production of the compound according to claim 2, which process comprises deprotecting a compound of



II

formula II:

wherein $R_1$ and $R_2$ are as defined in claim 2,
$R_6$ is $C_{1-6}$alkyl or benyl,
$R_7$ is an amino protecting goup,
and optionally converting the compound of formula I obtained in free form to a salt form or *vice versa*.

10. (Withdrawn by the Examiner) A method for treating or preventing disorders or diseases mediated by lymphocytes, acute or chronic transplant rejection, T-

cell mediated inflammatory or autoimmune diseases, diabetes, allergic diseases, myocarditis, hepatitis, ischemia/reperfusion injury, renal failure, hemmorhage shock, traumatic shock, cancer or infectious diseases, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.